Oncology

If approved, pembrolizumab in combination with lenvatinib will be indicated for the first-line treatment of advanced unresectable hepatocellular carcinoma.

A specialty pharmacy’s specific expertise and experience in supporting patients with cancer is among its most essential attributes.

A novel potential biomarker test could identify patients who would benefit from more advanced lung cancer screening.

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.

Top news of the day from across the health care landscape.

Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.

Insulin levels in the mother's body during fetal development or possible changes to the mother's DNA expression passed to her offspring may increase the risk for developing leukemia.

Research highlights the importance of reaching non-white and younger populations with skin cancer prevention messages.

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer.

New study demonstrates a novel approach of linking HER2-targeting antibodies with chemotherapy drugs for patients with breast cancer.

Research adds to a previously found correlation between yogurt consumption and a lowered risk of bowel cancer.

There are currently an estimated 8.1 million males and 8.8 million females in the United States with a history of cancer.

A protein called DDX3X has been found to regulate a melanoma-specific oncogene called MITF that is central to the development of the pigment cells in the skin.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

As young patients with bone cancer are often treated with high doses of chemotherapy before and after surgery, researchers wanted to develop gentler treatment options.

FOXA1 has been previously known to be mutated in prostate cancer; however, its biological functions were not understood well.

Specific types of cancer—such as bone, kidney, throat, and uterine—also had a higher incidence of chronic and severe pain that restricted daily activity.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Officials with the FDA approved Amgen’s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.